DSCDI | 191794-44-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: DSCDI
• 英文别名: 4-imidazol-1-yl-N-[2-[2-[(4-imidazol-1-yl-4-oxobutanoyl)amino]ethyldisulfanyl]ethyl]-4-oxobutanamide
• CAS: 191794-44-2
• 化学式: C₁₈H₂₄N₆O₄S₂
• 分子量: 452.558
• InChiKey: SJDWHZJKCVAIPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  30
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  179
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  DSCDI 在 盐酸 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 N-[2-(2-aminoethyldisulfanyl)ethyl]-N'-[2-[2-[[4-[2-(2-aminoethyldisulfanyl)ethylamino]-4-oxobutanoyl]amino]ethyldisulfanyl]ethyl]butanediamide;hydrochloride
  参考文献：
  名称：

  Synthesis and in vitro evaluation of novel pro-drugs for the treatment of nephropathic cystinosis

  摘要：

  As part of our continuing work to obtain new pro-drugs for the treatment of nephropathic cystinosis, a number of glutaric and succinic acid derivatives of cystamine have been designed, synthesised and biologically evaluated in vitro. These compounds have been designed as odourless and tasteless pro-drugs which will release multiple molecules of cysteamine upon administration. All of the synthesised compounds evaluated in this study were non-cytotoxic and displayed a greater ability than cysteamine to deplete the levels of cystine in cultured fibroblasts. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.04.022
• 作为产物：
  描述：

  N,N'-(3,4-dithia-hexanediyl)-bis-succinamic acid 、 N,N'-羰基二咪唑 以 N,N-二甲基甲酰胺 为溶剂， 以90%的产率得到DSCDI
  参考文献：
  名称：

  DIHYDRAZIDE COMPOUNDS, PREPARATION AND USES THEREOF

  摘要：

  揭示了具有化学式（I）或（II）的双肼化合物，其中R1-R4为烷基，取代烷基，芳基或聚醚基团。提供了制备这些双肼化合物的医用水凝胶和药物控释载体的用途。

  公开号：

  US20100048952A1

文献信息

• PEGylated derivatives of cystamine as enhanced treatments for nephropathic cystinosis
  作者：Ziad Omran、Graeme Kay、Alberto Di Salvo、Rachel M. Knott、Donald Cairns

  DOI：10.1016/j.bmcl.2010.11.085

  日期：2011.1

  The genetic disease, nephropathic cystinosis is characterized by lysosomal accumulation of the amino acid cystine. Crystallization of cystine in affected organs, if untreated, results in mortality of the affected individuals by their middle to late teens. The only approved treatment for cystinosis is administration of cysteamine. However, cysteamine is associated with an offending odor and taste and this, coupled to a rapid first pass metabolism and a 6 h dosing regimen, suggest a clear need to improve the therapy. A number of PEGylated derivatives of cystamine, the disulfide counterpart of cysteamine, have been synthesised and evaluated in cultured cystinotic fibroblasts for toxicity and efficacy. All of the tested compounds were non-cytotoxic and displayed a remarkable depletion of intralysosomal cystine. (C) 2010 Elsevier Ltd. All rights reserved.
• Synthesis and in vitro evaluation of novel pro-drugs for the treatment of nephropathic cystinosis
  作者：Ziad Omran、Kevin A. Moloney、Amina Benylles、Graeme Kay、Rachel M. Knott、Donald Cairns

  DOI：10.1016/j.bmc.2011.04.022

  日期：2011.6

  As part of our continuing work to obtain new pro-drugs for the treatment of nephropathic cystinosis, a number of glutaric and succinic acid derivatives of cystamine have been designed, synthesised and biologically evaluated in vitro. These compounds have been designed as odourless and tasteless pro-drugs which will release multiple molecules of cysteamine upon administration. All of the synthesised compounds evaluated in this study were non-cytotoxic and displayed a greater ability than cysteamine to deplete the levels of cystine in cultured fibroblasts. (C) 2011 Elsevier Ltd. All rights reserved.
• DIHYDRAZIDE COMPOUNDS, PREPARATION AND USES THEREOF
  申请人：Bioregen Biomedical (Changzhou) Co., Ltd.

  公开号：EP2088140B1

  公开（公告）日：2013-05-15